Cronus Pharma Launches Butorphic® (Butorphanol Tartrate) Sterile Injectable Solution
"Butorphic is a vital analgesic for managing equine colic pain and we are excited to grow our equine portfolio. Importantly, Butorphic marks our fifth product launch this year, expanding our portfolio to twenty-five products with several more planned for 2025 and beyond," said Vimal Kavuru, Chairman & CEO.
This launch enhances Cronus Pharma's robust sedative and anesthesia product portfolio which includes AnaSed® Equine (Xylazine) Injection, Cropamezole™ (Atipamezole) Injection, DexmedVet™ (Dexmedetomidine) Injection, DetomiSed™ (Detomidine) Injection, and Ketamine Injection.
"Butorphic's launch reinforces our position among the animal health leaders in U.S. FDA ANADA approvals over the past several years, which is a testament to our team's dedication to delivering high-quality, cost-effective pharmaceuticals to veterinarians and pet owners," said Edward Neugeboren, Chief Strategy Officer.
Butorphic is indicated for the relief of pain associated with colic and postpartum pain in adult horses and yearlings. Clinical studies demonstrate that butorphanol tartrate effectively alleviates abdominal pain caused by torsion, impaction, intussusception, spasmodic and tympanic colic, and postpartum pain. Approved by the FDA under ANADA #200-332, Butorphic provides the same efficacy and safety, and is a generic equivalent to the reference product, Torbugesic®. Available in 10 mg/mL concentrations in 20 mL and 50 mL multi-dose vials, our unique 20 mL vial offers veterinarians more flexible dosing options.
Please refer to the Package Insert for complete prescribing instructions, precautions, and full safety information.
About Cronus Pharma
Cronus is a fully integrated research, development, manufacturing, sales and marketing animal health pharmaceutical company headquartered in East Brunswick, New Jersey, dedicated to providing high-quality and cost-effective pharmaceuticals serving the companion, equine and production animal health markets. Through our in-house R&D and acquisitions, Cronus has an extensive product portfolio of seventy-seven US FDA approved products as well as numerous products pending approval and a broad development pipeline. Cronus is proud to be among the leaders in U.S FDA ANADA approvals in the animal health industry over the past several years. Our recently built state of the art manufacturing facility located in Hyderabad, India has broad capabilities including solid oral dose, sterile injectables and cephalosporins. Our products are available to veterinarians and pet owners nationwide through national and regional distributors. Our passionate team is committed to growing our business and being among the leading animal health pharmaceutical companies.
Additional information is available at www.cronuspharmausa.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
Asia Pacific Firms Use Google Cloud to Modernize, Innovate
SYDNEY--(BUSINESS WIRE)--Enterprises in Asia Pacific are adopting Google Cloud solutions to remain competitive by modernizing complex IT infrastructure and making better use of data, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. Companies in Asia Pacific need to move data and workloads from legacy systems to modern, scalable platforms for future agility. Many are turning to Google and its provider partners for the tools and services they need for that transition. The 2025 ISG Provider Lens ® Google Cloud Partner Ecosystem report for Asia Pacific finds that companies in the region are transforming their digital infrastructures through cloud migration and data innovation. While keeping up with rapidly evolving technologies, enterprises in Asia Pacific are also under growing pressure to control costs, making it imperative that they maximize their return on cloud investments. Google Cloud's focus on addressing these challenges positions it as a preferred partner in the region. 'Companies in Asia Pacific need to move data and workloads from legacy systems to modern, scalable platforms for future agility,' said Michael Gale, partner and regional leader, ISG Asia Pacific. 'Many are turning to Google and its provider partners for the tools and services they need for that transition.' Demand for cloud services is rising quickly in Asia Pacific, accelerated by the need for better flexibility and operational performance, the report says. Companies need effective, reliable cloud solutions to support a growing number of applications, including business intelligence and customer relationship management. Cloud adoption varies widely with differing levels of digital maturity in the region. Established markets such as Australia and New Zealand lead in advanced cloud solutions, while companies in emerging markets are rapidly integrating cloud services. In Southeast Asia, some governments are encouraging the trend with initiatives to promote digital economies. Generative AI is also gaining traction among enterprises in the region as companies begin to see it as essential for improved operational efficiency and customer engagement, ISG says. Enterprises are exploring GenAI applications including chatbots, predictive analytics and workflow automation. Google Cloud's AI and ML tools, such as Vertex AI, are becoming integral to these efforts. The rise of AI in Asia Pacific is also increasing demand for managed services to deploy and run AI solutions. Many enterprises in Asia Pacific are adopting hybrid cloud and multicloud strategies to balance flexibility, scalability and control by combining on-premises and public cloud resources, the report says. They are turning to service providers offering comprehensive support for these strategies, including tools such as Google Anthos for workload management across clouds. The rising importance of advanced analytics and data visualization in the region also is driving adoption of Google Cloud solutions, ISG says. Companies are seeking real-time analytics backed by a focus on data quality and governance. 'Enterprises in Asia Pacific are recognizing that their data needs to be accurate, accessible and compliant with data protection laws,' said Sonam Chawla, lead analyst, ISG Provider Lens Research, and lead author of the report. 'Solutions that support these strategic objectives help to create trust among companies and their partners.' The report also examines other trends in the Asia Pacific Google Cloud ecosystem, including growing demand for AI-enabled supply chain management and the rising need for data localization and security to comply with national laws. For more insights into Google Cloud-related challenges facing enterprises in Asia Pacific, plus ISG's advice for addressing them, see the ISG Provider Lens ® Focal Points briefing here. The 2025 ISG Provider Lens ® Google Cloud Partner Ecosystem report for Asia Pacific evaluates the capabilities of 32 providers across four quadrants: Google Cloud Professional Services (Consulting and Migration), Google Cloud Managed Services, Google Cloud Enterprise Data Infrastructure Services and Google Cloud GenAI and AI Services. The report names Accenture, Capgemini, Cognizant, HCLTech, Infosys, Persistent Systems, TCS and Wipro as Leaders in all four quadrants. It names Tech Mahindra as a Leader in two quadrants and DXC Technology, LTIMindtree, Mantel Group and Quantiphi as Leaders in one quadrant each. In addition, NTT DATA is named as a Rising Stars — a company with a 'promising portfolio' and 'high future potential' by ISG's definition — in two quadrants. Cloud4C and Searce are named as Rising Stars in one quadrant each. In the area of customer experience, Persistent Systems is named the global ISG CX Star Performer for 2025 among Google Cloud Partners Ecosystem providers. Persistent Systems earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry. The 2025 ISG Provider Lens ® Google Cloud Partner Ecosystem report for Asia Pacific is available to subscribers or for one-time purchase on this webpage. About ISG Provider Lens ® Research The ISG Provider Lens ® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
Yahoo
2 hours ago
- Yahoo
MultiTech Launches CT300 Wireless Current Transformer for Scalable, Energy Monitoring
MultiTech has released the CT300, a wireless, self-powered current transformer designed to simplify energy monitoring in commercial and industrial environments. Using LoRaWAN® connectivity, the CT300 delivers minute-by-minute energy insights without the need for external power, batteries, or complex wiring—making it ideal for retrofits and large-scale deployments. The clamp-on sensor installs in minutes with zero downtime and enables facility managers, sustainability teams, and system integrators to optimize efficiency, reduce energy waste, and gain actionable visibility into electrical loads. MOUNDS VIEW, Minn., July 24, 2025 /PRNewswire-PRWeb/ -- Self-powered LoRaWAN® sensor delivers actionable energy insights without complex wiring or batteries MultiTech, a leading global supplier of Internet of Things (IoT) devices and services, today announced the launch of the CT300, a cutting-edge, wireless current transformer designed to provide energy usage data with unmatched ease and flexibility. The CT300 supports scalable deployments across commercial and industrial applications—enabling facility managers, sustainability teams, system integrators, and equipment owners to unlock greater efficiency, reduce energy waste, and improve operational visibility. Unlike traditional solutions, the CT300 is self-powered and transmits data via LoRaWAN®, eliminating the need for external power sources or complicated wiring. Designed for fast, non-intrusive installation, it simply clamps around existing conductors—ideal for both retrofits and new deployments. "The CT300 is a game-changer for facility teams looking to digitize energy monitoring without disrupting operations," said Angela McBride, Facility Operations Director at a Fortune 500 manufacturer. "We deployed the CT300 in minutes and identified areas where we could cut costs and improve performance." "It's the perfect tool for integrators like us," said Carlos Reyes, Principal Engineer at EcoEdge Automation. "You get enterprise-grade energy visibility in a compact, easy-to-install sensor. No wires, no batteries, and no headaches." "For sustainability teams focused on measurable results, the CT300 provides the kind of granularity and reliability we've been waiting for," added Morgan Liu, Energy & ESG Analyst. "It makes tracking Scope 2 emissions and ROI on retrofits much more accessible." The CT300 is now available through MultiTech's global distribution network and includes native integration with MultiTech Device Management tools for remote monitoring and configuration. Key Features of the CT300: Minute-by-Minute Monitoring: Capture current draw across individual circuits and assets Wireless & Self-Powered: No external power or batteries required LoRaWAN® Connectivity: Secure, long-range communication across indoor and outdoor environments Non-Invasive Installation: Clamp-on design for fast deployment with zero downtime Maintenance-Free Operation: Ideal for large-scale or hard-to-access installations Industries Served: Commercial buildings, manufacturing, logistics, data centers, retail, healthcare, education, and smart cities ________________________________________ Learn More and Get Started: Explore the product page: Request a demo or consultation: sales@ Download the CT300 datasheet: Download Media Contact Matthew MacDowell, MultiTech, +1 763-717-5528, MMacDowell@ Twitter View original content: SOURCE MultiTech Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved Stockholders are encouraged to vote FOR Proposals 2 and 3 by Calling 1-877-750-8310 (from the U.S. and Canada) or +1-412-232-3651 (from other countries) IRVINE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it conducted a Special Meeting of Stockholders and partially adjourned the meeting for Proposal 2, the proposal to approve the sale of substantially all of ReShape's assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd. (Asset Sale Proposal), and Proposal 3, the proposal to approve and adopt proposed amendments to ReShape's certificate of incorporation in connection with ReShape's proposed merger (Merger) with Vyome Therapeutics, Inc. (Charter Amendment Proposal). All other proposals required for the Merger were approved by stockholders. ReShape adjourned the Special Meeting of Stockholders with respect to the Asset Sale Proposal and Charter Amendment Proposal to allow additional time to solicit proxies with respect to these proposals. Approval of the Asset Sale Proposal and the Charter Amendment Proposal are conditions to the consummation of the Merger. Addressing the Company's stockholders, Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences, noted, 'Our ability to complete the Merger, which we believe will maximize value for our stockholders, is contingent upon approval of the Asset Sale Proposal and the Charter Amendment Proposal. Your vote for the Asset Sale Proposal is key to the Merger, and your vote for the Charter Amendment Proposal is important for the operation of the combined company following the Merger.' The Special Meeting of Stockholders will resume with respect to the Asset Sale Proposal and the Charter Amendment Proposal on Thursday, August 7, 2025 at 11:30 a.m. Eastern Time. The reconvened meeting will be held virtually at The record date for determining stockholders eligible to vote at the Special Meeting of Stockholders remains the same, June 9, 2025. ReShape encourages all stockholders of record as of June 9, 2025 that have not yet submitted proxies to submit proxies in favor of the Asset Sale Proposal and the Charter Amendment Proposal and to do so promptly. Those who voted against these proposals are asked to please reconsider their votes based on the factors described in this press release. The proxy statement for the Special Meeting of Stockholders of ReShape filed on June 24, 2025 contains important information, and this press release should be read in conjunction with the proxy statement, which, along with other relevant materials, is available at no charge at the U.S. Securities and Exchange Commission's website and at the Company's website YOUR VOTE IS VERY IMPORTANT!Stockholders can vote by telephone, or via the follow the easy instructions on the proxy card or voting instruction form previously sent. For any questions or assistance in voting shares, please call our proxy solicitor, INNISFREE M&A INCORPORATEDTOLL-FREE, at 1-877-750-8310 (from the U.S. and Canada)or +1-412-232-3651 (from other countries) About Vyome Vyome Therapeutics is building a healthcare platform spanning the US-India innovation corridor. Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immune-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. Based in Cambridge, MA, the company has announced its intent to be listed on the Nasdaq exchange under the ticker 'HIND' pursuant to a reverse merger with ReShape Lifesciences Inc. (Nasdaq: RSLS) in early 2025. To learn more, please visit About Biorad MedisysBiorad Medisys Pvt. Ltd.® is a rapidly growing med-tech company dedicated to redefining healthcare standards with precision-engineered medical devices backed by rigorous scientific research. It operates three business units – Indovasive, Orthovasive and Neurovasive. Indovasive offers consumables and equipment in Urology and Gastroenterology. The Orthovasive segment sells a complete range of Knee and Hip implants for both Primary and Revision surgeries. It has recently forayed into Neurovascular BU for selling a wide portfolio of products in peripheral vascular, neurovascular and rehabilitation segments. It has two manufacturing facilities in India and is currently exporting to 50+ countries. To realize its global expansion strategy, it recently acquired a Swiss based company, Marflow, which specializes in commercialization of products in Urology & Gastroenterology. About ReShape Lifesciences® ReShape Lifesciences® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit Forward-Looking Safe Harbor Statement This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission (SEC), including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law. Additional InformationIn connection with the proposed Merger and sale of assets to Ninjour Health International Limited, an affiliate of Biorad Medisys Pvt. Ltd. (Asset Sale), ReShape filed with the SEC on June 24, 2025 and mailed or otherwise provided to its stockholders the joint proxy statement/prospectus (joint proxy statement/prospectus) and other relevant documents in connection with the proposed Merger and Asset Sale. Before making a voting decision, ReShape's stockholders are urged to read the joint proxy statement/prospectus and any other documents filed by ReShape with the SEC in connection with the proposed Merger and Asset Sale or incorporated by reference therein carefully and in their entirety because they contain important information about ReShape, Vyome and the proposed transactions. Investors and stockholders may obtain a free copy of these materials and other documents filed by ReShape with the SEC at the SEC's website at at ReShape's website at or by sending a written request to ReShape at 18 Technology Drive, Suite 110, Irvine, California 92618, Attention: Corporate Secretary. CONTACTSReShape Lifesciences Investor Contact:Paul F. HickeyPresident and Chief Executive Officer949-276-7223ir@ Investor Relations Contact:Rx Communications GroupMichael Miller(917)-633-6086mmiller@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
